Latest Insider Transactions at Arrowhead Pharmaceuticals, Inc. (ARWR)
This section provides a real-time view of insider transactions for Arrowhead Pharmaceuticals, Inc. (ARWR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARROWHEAD PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARROWHEAD PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 11
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,597
-2.54%
|
$939,357
$81.02 P/Share
|
|
Jan 07
2021
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,625
-12.5%
|
$1,171,875
$75.0 P/Share
|
|
Jan 06
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,625
-2.11%
|
$2,174,375
$71.72 P/Share
|
|
Jan 06
2021
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-2.67%
|
$1,775,000
$71.91 P/Share
|
|
Jan 06
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
19,375
-4.25%
|
$1,375,625
$71.87 P/Share
|
|
Jan 05
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
19,375
-2.87%
|
$1,395,000
$72.53 P/Share
|
|
Jan 04
2021
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,750
-11.03%
|
$285,000
$76.08 P/Share
|
|
Jan 04
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
4,000
-3.24%
|
$304,000
$76.08 P/Share
|
|
Jan 04
2021
|
Michael S Perry Director |
SELL
Open market or private sale
|
Direct |
4,000
-4.26%
|
$304,000
$76.09 P/Share
|
|
Jan 01
2021
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+20.93%
|
-
|
|
Jan 01
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+22.22%
|
-
|
|
Jan 01
2021
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,500
+7.15%
|
-
|
|
Jan 01
2021
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+8.74%
|
-
|
|
Jan 01
2021
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+39.13%
|
-
|
|
Jan 01
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+10.96%
|
-
|
|
Jan 01
2021
|
Marianne De Backer Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+25.35%
|
-
|
|
Jan 01
2021
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+18.38%
|
-
|
|
Jan 01
2021
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+15.86%
|
-
|
|
Jan 01
2021
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+19.3%
|
-
|
|
Dec 30
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
599
-0.02%
|
-
|
|
Dec 28
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,126
-0.04%
|
-
|
|
Dec 22
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
35
-0.03%
|
-
|
|
Dec 21
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
235
-0.1%
|
-
|
|
Dec 18
2020
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,510
+0.79%
|
$202,550
$5.45 P/Share
|
|
Dec 17
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
600
-0.09%
|
-
|
|
Dec 17
2020
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
500
-3.23%
|
$39,500
$79.59 P/Share
|
|
Dec 17
2020
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
9,075
-7.33%
|
$716,925
$79.3 P/Share
|
|
Dec 10
2020
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,000
-5.5%
|
$210,000
$70.8 P/Share
|
|
Dec 09
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
38,676
-0.38%
|
$2,668,644
$69.89 P/Share
|
|
Dec 09
2020
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
38,676
+1.5%
|
$77,352
$2.01 P/Share
|
|
Dec 08
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,324
-0.65%
|
$1,093,708
$67.97 P/Share
|
|
Dec 08
2020
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,324
+0.64%
|
$32,648
$2.01 P/Share
|
|
Dec 07
2020
|
Douglas B Given Director |
BUY
Bona fide gift
|
Indirect |
31,000
+50.0%
|
-
|
|
Dec 07
2020
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
31,000
-20.02%
|
-
|
|
Dec 04
2020
|
Patrick O'Brien COO and General Counsel |
SELL
Bona fide gift
|
Direct |
800
-0.23%
|
-
|
|
Nov 20
2020
|
Curt Bradshaw Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,625
-100.0%
|
$1,062,500
$68.73 P/Share
|
|
Nov 19
2020
|
Curt Bradshaw Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,625
-50.0%
|
$1,078,125
$69.39 P/Share
|
|
Nov 19
2020
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,500
-13.0%
|
$1,345,500
$69.39 P/Share
|
|
Nov 09
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
43,505
-4.73%
|
$3,001,845
$69.45 P/Share
|
|
Nov 09
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,505
+8.45%
|
$609,070
$14.54 P/Share
|
|
Oct 23
2020
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-1.93%
|
$5,800,000
$58.37 P/Share
|
|
Oct 20
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,166
-6.38%
|
$1,574,964
$54.04 P/Share
|
|
Oct 20
2020
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,166
+6.0%
|
$174,996
$6.15 P/Share
|
|
Oct 09
2020
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
10,000
-24.41%
|
$480,000
$48.0 P/Share
|
|
Oct 08
2020
|
Marianne De Backer Director |
BUY
Open market or private purchase
|
Direct |
1,000
+2.82%
|
$50,000
$50.47 P/Share
|